Clinical trials: Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

• Unknown status
• Age: 18 years and older
• Phase 1/2

The study is a first-in-human [FIH], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component.

Trial name

NCT05842785

Testing

Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma

Where

China

Volunteers

162 people

Sponsor

Tyligand Bioscience (Shanghai) Limited